{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-061848","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2023-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.299550+00:00","generated_at":"2026-06-14T22:30:53.730084+00:00","sec_items":["1.01","3.02","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acurx Pharma prices $4M registered direct offering of common stock and warrants","bullets":["Gross proceeds of ~$4M from sale of 1,333,333 shares (or pre-funded warrants) at $3.00 per share.","Concurrent private placement of Series C and D warrants to purchase up to 2,666,666 shares at $3.26, exercisable after 6 months.","Existing Series A and B warrants amended to extend expiry to May 18, 2029.","Offering expected to close May 18, 2023; Maxim Group LLC as placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-061848","json":"https://secwatch.observer/filing/0001104659-23-061848.json","markdown":"https://secwatch.observer/filing/0001104659-23-061848.md","text":"https://secwatch.observer/filing/0001104659-23-061848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/tm2315976d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T22:30:53.730084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35f23b7d4a15294b72fab09a0ac17bfc209af59f","claim":"Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with a single healthcare-focused U.S. institutional investor named therein (the \"Investor\") valued at approximately $4.0 million (effective 2023-05-16).","evidence_excerpt":"On May 16, 2023, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused U.S. institutional investor named therein (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “Registered Offering”), (i) an aggregate of 601,851 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (“Common Stock”), at an offering price of $3.00 per share and (ii) an aggregate of 731,482 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) at an offering price of $2.9999 per Pre-Funded Warrant, for aggregate gross proceeds from the Registered Offering of approximately $4.0 million before deducting the placement agent fee and related offering expenses.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a single healthcare-focused U.S. institutional investor named therein (the \"Investor\")"},{"label":"Value","value":"approximately $4.0 million"},{"label":"Effective","value":"2023-05-16"}],"fact_type":"material_agreement"},{"claim_id":"593b3fece2d968e7f43d3e72264c59de2bedd2f5","claim":"Acurx Pharmaceuticals, Inc. entered into Placement Agent Agreement with Maxim Group LLC (effective 2022-05-16).","evidence_excerpt":"On May 16, 2022, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Maxim Group LLC (the “Placement Agent”) pursuant to which the Company engaged Maxim as the placement agent in connection with the Offerings.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2022-05-16"}],"fact_type":"material_agreement"},{"claim_id":"e0d1f8987656fb97cb10950a811c82d6ac7981b3","claim":"Acurx Pharmaceuticals, Inc. amended Warrant Amendment Agreement with the Investor.","evidence_excerpt":"In connection with the Offerings, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"the Investor"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}